Used in the treatment of hematologic malignancies, particularly acute myeloid leukemia (AML) and certain B-cell lymphomas. It targets CD70 (CD27 ligand), which is overexpressed on cancer cells but limited in healthy tissues, enabling selective immune attack. By binding to CD70, it blocks the CD27-CD70 signaling pathway involved in tumor cell survival and immune evasion. This promotes antibody-dependent cellular cytotoxicity (ADCC) and supports T-cell activation, enhancing anti-tumor immune responses. Investigated in clinical trials as a monotherapy and in combination with other agents like hypomethylating drugs to improve outcomes in relapsed or refractory cancers.